{"transactions":[{"id":819873,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":4.25,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819872,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":12000,"derivative":{"exercise_price":0.615,"expiration_date":"2033-01-05","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819871,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025.  In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025."}],"balance_after":0,"derivative":{"exercise_price":2.89,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819870,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025.  In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025."}],"balance_after":150000,"derivative":{"exercise_price":0.615,"expiration_date":"2035-02-24","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819869,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":5.15,"expiration_date":"2034-10-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819868,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":200000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":200000,"derivative":{"exercise_price":0.615,"expiration_date":"2034-10-28","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819867,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819866,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":7100,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":7100,"derivative":{"exercise_price":0.615,"expiration_date":"2033-11-06","underlying":"Common Stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819865,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":14.56,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819864,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":75000,"derivative":{"exercise_price":0.61,"expiration_date":"2034-02-28","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819863,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17004,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":17004},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":819862,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-02T18:21:09.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":17004,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested."}],"balance_after":17004,"derivative":{"exercise_price":0.615,"expiration_date":"2033-09-29","underlying":"Common Stock","underlying_shares":17004},"source":{"system":"sec-edgar","filing":"0001628280-26-023356","document":"wk-form4_1775168465.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026023356/wk-form4_1775168465.xml","form_type":"4"}},{"id":914586,"issuer":{"id":8098,"kind":"organization","name":"Skye Bioscience, Inc.","symbol":"SKYE"},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-09T20:54:39.000Z","date":"2026-02-06","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in equal monthly installments over the four-year period beginning January 19, 2026."}],"balance_after":150000,"derivative":{"exercise_price":0.82,"expiration_date":"2036-02-06","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001628280-26-006623","document":"wk-form4_1770688476.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000162828026006623/wk-form4_1770688476.xml","form_type":"4"}},{"id":2340090,"issuer":{"id":8639,"kind":"organization","name":"ZyVersa Therapeutics, Inc."},"owners":[{"id":54282,"kind":"person","name":"Twitty Christopher","position":1,"cik":"0001870121","reported_name":"Twitty Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B common stock","published_at":"2022-03-10T17:30:58.000Z","date":"2022-01-06","kind":"other","acquired":false,"shares":953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"kind","element":"transactionCoding","label":"F2","text":"As contemplated in connection with the initial public offering of the Issuer, 953 shares of Class B common stock of the Issuer were forfeited for no consideration and cancelled because the underwriters of the Issuer's initial public offering did not exercise their over-allotment option in full, as described in the Issuer's Registration Statement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"As described in the Issuer's registration statement on Form S-1 (File No. 333-256056) (the \"Registration Statement\") under the section entitled \"Description of Securities - Founder Shares,\" the shares of Class B Common Stock, par value $0.0001 per share, will automatically be converted into shares of Class A Common Stock, par value $0.0001 per share, at the time of the Issuer's initial business combination, on a one-for-one basis, subject to certain adjustment described therein, and have no expiration date"}],"balance_after":8631,"derivative":{"underlying":"Class A common stock","underlying_shares":953},"source":{"system":"sec-edgar","filing":"0001213900-22-011643","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1870121/000121390022011643/ownership.xml","form_type":"4"}}]}